首页> 外文会议>North American Thermal Analysis Society conference >Amorphous Content Quantification by DSC and DVS. Comparative Approach to Method Development and Validation
【24h】

Amorphous Content Quantification by DSC and DVS. Comparative Approach to Method Development and Validation

机译:通过DSC和DVS进行非晶含量定量。方法开发和验证的比较方法

获取原文

摘要

The presence of various amounts of amorphous material formed either during crystallisation or processing may affect significantly the properties and the stability of the pharmaceutical substances. Some critical properties affecting the bioavailability of product and efficacy, like dissolution rate may be enhanced, while chemical and physical stability will decrease. This can have a direct influence during the lifecycle of the pharmaceutical substance, that is, in the processing steps, storage and delivery to the patient. In order to fully characterise the whole pharmaceutical substance it is therefore necessary to develop methods to quantify the amorphous material. This study shows different approaches to the development and validation of DSC and DVS methods for some drug substances and excipients being developed in our company. Knowledge of the product and its physical behaviour is essential to succeed in the development of an accurate and sensitive method. This study shows a description of the main parameters considered for the development of DSC and DVS methods for amorphous quantification. In DSC methods, the use of the crystallization enthalpy versus the step on the glass transition temperature (Tg) is assessed. Examples of DVS methods are shown using different temperatures, different relative humidity (RH) steps, different solvents and varying times for each step depending on the kinetics of the solvent-product system. The validation strategy followed in this study is based on the principles behind ICH Q2 (Rl) Validation Of Analytical Procedures: Text And Methodology. DSC methods are faster than DVS methods and those may be the selected ones when the amount of amorphous is significant. But for the quantification of small amounts of amorphous DSC methods are used mainly in early stages or as in-process control. For such uses either no validation or a reduced validation is required. DVS methods are used during development phases when an accurate assessment of the amorphous content is required. In late development and commercial phases a DVS method as a limit test may be the most appropriate approach. Comparison of LOQ for different products will be presented. Values for DVS methods are always lower than for DSC methods, as expected. Also a strong product dependence is observed. In some cases the development of a Hyper-DSC method is envisaged as an optimal solution that can provide a fast method with a low LOQ as with DVS methods. That will be shown in future studies.
机译:在结晶或加工过程中形成的各种无定形物质的存在可能会严重影响药物的性质和稳定性。一些影响产品生物利用度和功效的关键特性,例如溶出速率可能会提高,而化学和物理稳定性会下降。这在药物生命周期中,即在加工步骤中,对患者的存储和输送有直接影响。为了完全表征整个药物物质,因此有必要开发量化无定形物质的方法。这项研究显示了针对我们公司正在开发的某些原料药和赋形剂开发和验证DSC和DVS方法的不同方法。对产品及其物理行为的了解对于成功开发准确而敏感的方法至关重要。这项研究显示了开发DSC和DVS方法进行无定形定量分析所考虑的主要参数的描述。在DSC方法中,相对于玻璃化转变温度(Tg)上的台阶,评估了结晶焓的使用。显示了DVS方法的示例,这些步骤使用不同的温度,不同的相对湿度(RH)步骤,不同的溶剂以及每个步骤的时间不同,具体取决于溶剂-产物系统的动力学。这项研究中遵循的验证策略基于ICH Q2(R1)分析程序验证背后的原理:文本和方法。 DSC方法比DVS方法快,当无定形量很大时,可以选择DSC方法。但是对于定量无定形DSC的方法,主要用于早期阶段或作为过程中的控制方法。对于此类用途,不需要验证或减少验证。当需要精确评估非晶态含量时,在开发阶段使用DVS方法。在后期开发和商业阶段,DVS方法作为极限测试可能是最合适的方法。将介绍不同产品的LOQ的比较。正如预期的那样,DVS方法的值始终低于DSC方法的值。还观察到强烈的产品依赖性。在某些情况下,可以将Hyper-DSC方法的开发视为一种最佳解决方案,该解决方案可以像DVS方法一样提供具有低LOQ的快速方法。这将在以后的研究中显示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号